FDA Delays Approval of Moderna Vaccine for Adolescent Vaccination
In a weekend statement, Moderna stated that the US FDA needs more time to evaluate the international analysis of rare myocarditis caused by the vaccine, which means that the regulator may not be able to approve the vaccine for use within the year. Youth vaccination. Affected by this news, the company's stock price fell nearly 7% after the opening on Monday, but then continued to rise, closing the day with a drop of 2.33%.
$Moderna(MRNA.US)$
精彩评论